Future oncology最新文献_第10页

Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States? 简单的语言总结：种族或收入状况是否影响转移性去势敏感前列腺癌（mCSPC）患者在美国接受的癌症治疗？

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-25 DOI: 10.1080/14796694.2025.2485763

Daniel J George, Neeraj Agarwal, Krishnan Ramaswamy, Zachary Klaassen, Rhonda L Bitting, David Russell, Rickard Sandin, Birol Emir, Hongbo Yang, Wei Song, Yilu Lin, Agnes Hong, Wei Gao, Stephen J Freedland

引用次数: 0

Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients. 达罗卢胺加雄激素剥夺治疗：ARASEC与既往临床试验患者的倾向评分匹配。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-01 DOI: 10.1080/14796694.2025.2482360

Rana R McKay, Ashley E Ross, Mark A Preston, Justin R Gregg, Simpa S Salami, Natasha Littleton, Niculae Constantinovici, Shankar Srinivasan, Frank Verholen, Neal D Shore

{"title":"Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.","authors":"Rana R McKay, Ashley E Ross, Mark A Preston, Justin R Gregg, Simpa S Salami, Natasha Littleton, Niculae Constantinovici, Shankar Srinivasan, Frank Verholen, Neal D Shore","doi":"10.1080/14796694.2025.2482360","DOIUrl":"10.1080/14796694.2025.2482360","url":null,"abstract":"Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel is one of the standards of care for metastatic hormone-sensitive prostate cancer (mHSPC), based on the phase III ARASENS study. To provide the option to use darolutamide without docetaxel to meet patients' needs and preferences, the phase III placebo-controlled ARANOTE study was undertaken. Reflecting evolving treatment guidelines for mHSPC, the complementary US-based ARASEC study was designed with a single, prospectively-enrolled investigational arm (darolutamide plus ADT) and an ADT monotherapy arm derived from the previous phase III CHAARTED study. ARASEC was designed with the same eligibility criteria and assessments as CHAARTED, and patients were matched 1:1 using propensity scores calculated from key prognostic baseline variables: age, ECOG performance status, extent of disease, prior local therapy, Gleason score, and prostate-specific antigen level. ARASEC enrolled 223 patients who received darolutamide plus ADT, with 393 patients in the CHAARTED ADT control arm available for matching. Matching yielded 160 patients in each arm with minimal differences in prognostic variables between the matched groups, who will be compared to evaluate the efficacy and safety of darolutamide plus ADT in mHSPC. This novel study design may inform future single-arm trials with historical control arms, with potentially faster accrual and reduced costs.Clinical Trial Registration: NCT05059236.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1365-1375"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer. 维多汀和派姆单抗：重新定义先前未经治疗的晚期尿路上皮癌的护理标准

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-25 DOI: 10.1080/14796694.2025.2482363

Michal Sternschuss, Jonathan E Rosenberg

引用次数: 0

Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK. 转移性激素敏感前列腺癌的当代现实治疗：美国、四个欧洲国家和英国。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-26 DOI: 10.1080/14796694.2025.2481024

Peter J Goebell, Stephanie Chen, Jay Jhaveri

{"title":"Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK.","authors":"Peter J Goebell, Stephanie Chen, Jay Jhaveri","doi":"10.1080/14796694.2025.2481024","DOIUrl":"10.1080/14796694.2025.2481024","url":null,"abstract":"Aim: To characterize contemporary global real-world metastatic hormone-sensitive prostate cancer (mHSPC) treatment, guideline concordance, trends, and potential trend drivers.Materials and methods: Retrospective data from the Ipsos Global Oncology Monitor database for the United States, Germany, France, Spain, Italy, and the United Kingdom were used for descriptive analysis of mHSPC patients, treating physicians, and treatment utilization. Statistical testing of differences among treatment cohorts for the final study period was conducted.Results: Of 15,662 total mHSPC patients across countries (2019-2024), the 1404 patients from the most recent and relevant study period (August 2023-January 2024) had an average age of 72-74 years, good baseline functioning, high-risk prostate cancer features, and cardiometabolic conditions as top comorbidities. Treatment mostly occurred in hospital/institutional settings and urban locales by oncologists versus urologists. Monotherapy androgen deprivation therapy (mADT) use declined while use of novel androgen receptor inhibitor (nARI) combination therapies, especially doublets, increased. Concordance between real-world and guideline-recommended treatment varied by country, ranging from 43.8% to 61.6%.Conclusions: Concordance with guidelines improved globally driven by nARIs. Persistent use of mADT, a non-guideline-recommended therapy, indicates physicians' concern about the safety and trade-offs with current options. New therapies delivering greater net benefits are needed, along with education on guideline adherence.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1377-1390"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database. 乳腺癌化疗再挑战的间质性肺疾病复发：日本全国数据库。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-24 DOI: 10.1080/14796694.2025.2495543

Soichiro Nishijima, Keiko Sato, Tomohiro Onoue, Wataru Hashimoto, Mayumi Shikano

{"title":"Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database.","authors":"Soichiro Nishijima, Keiko Sato, Tomohiro Onoue, Wataru Hashimoto, Mayumi Shikano","doi":"10.1080/14796694.2025.2495543","DOIUrl":"10.1080/14796694.2025.2495543","url":null,"abstract":"Aim: The present study assessed the incidence of drug-induced interstitial lung disease (ILD) recurrence among breast cancer patients who underwent rechallenge with cancer-directed therapy.Materials & methods: Japanese insurance claims data and the Diagnosis Procedure Combination database (2009-2022) involving 81,601 patients were analyzed to evaluate 1,042 breast cancer patients who developed ILD. Of these, 566 patients underwent cancer-directed therapy rechallenge, and 42.1% of them were re-challenged with the same therapeutic regimen that caused the initial ILD.Results: ILD recurrence was observed in 18.9% of the patients, with a median recurrence time of 40 days. The drugs most commonly causing ILD were cytotoxic agents, and those most frequently used for rechallenge were cytotoxic agents.Conclusion: A notable ILD recurrence rate was observed in breast cancer patients after a cancer-directed therapy rechallenge, highlighting the need for cautious treatment planning and personalised strategies to balance cancer control while mitigating ILD risk.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 12","pages":"1525-1535"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC. nanory -312: NBTXR3 +放疗±西妥昔单抗治疗老年铂不合格局部晚期HNSCC的III期研究

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-05-05 DOI: 10.1080/14796694.2025.2496131

Christophe Le Tourneau, Zoltán Takácsi-Nagy, Sandra Nuyts, Sébastien Thureau, Feng Liu, Caroline Hoffmann, Trevor G Hackman, Maria Lesnik, Anaïs Debard, Laetitia Finzi, Kiran Devisetty, Omar I Vivar, Leonard A Farber, France Nguyen, Xavier Liem, Eteri Natelauri, Amanda Psyrri, Martin Burian, Jinming Yu, Sue S Yom

引用次数: 0

Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. 超越现状：当疾病体积和转移时间不足以对 mHSPC 进行个性化治疗时。

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-03-03 DOI: 10.1080/14796694.2025.2468569

Ángel Borque-Fernando, Teresa Alonso-Gordoa, María José Juan-Fita, Fernando Lopez Campos, Daniel Adolfo Pérez-Fentes, Antoni Vilaseca, Cristina Moretones Agut, Paola Usán, Pablo Maroto Rey

引用次数: 0

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. 前列腺癌患者ADT的持久性和依从性研究：美国的雷鲁高利、德格雷利克斯和GnRH激动剂。

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-04-06 DOI: 10.1080/14796694.2025.2480050

Jason Hafron, Agnes Hong, Michael J Ryan, Hela Romdhani, Frédéric Kinkead, Scott C Flanders, Rana R McKay

{"title":"Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.","authors":"Jason Hafron, Agnes Hong, Michael J Ryan, Hela Romdhani, Frédéric Kinkead, Scott C Flanders, Rana R McKay","doi":"10.1080/14796694.2025.2480050","DOIUrl":"10.1080/14796694.2025.2480050","url":null,"abstract":"Aims: Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral ADT, with limited real-world data on therapy persistence and adherence. This retrospective study evaluates persistence and adherence of relugolix, degarelix, and GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using data from the IBM MarketScan Research Database (Jan 2017 - Dec 2022).Methods: The IBM MarketScan Research Database (1 January 2017 - 31 December 2022) was used for enrollment history and claims. ADT adherence was measured by the proportion of days covered (PDC) at 3, 6, and 12 months, calculated as days on ADT divided by period duration. Kaplan-Meier analysis assessed treatment persistence by measuring time to treatment discontinuation.Results: Relugolix had higher adherence (PDC ≥ 80%) at 12 months (60.8%) compared to degarelix (13.0%) and GnRH agonists (46.3%). Median time to discontinuation was also longer for relugolix (13.5 months) than degarelix (3.1 months) and GnRH agonists (8.8 months). Persistence and adherence rates were higher in metastatic prostate cancer.Conclusions: Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1219-1230"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases. TUXEDO-4：曲妥珠单抗-德鲁西替康治疗her2低乳腺癌伴新发或进展性脑转移的II期研究

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-02-28 DOI: 10.1080/14796694.2025.2470604

Maximilian Marhold, Marta Vaz Batista, Isabel Blancas, Cristina Morales, Cristina Saura-Manich, Cristina Saavedra, Manuel Ruíz-Borrego, Patricia Cortez, Felipe Slebe, Marta Campolier, Juliana Carvalho Santos, José Antonio Guerrero-Martínez, Carlos Jiménez-Cortegana, Beate Rottenmanner, Heidrun Forstner, Rupert Bartsch, Matthias Preusser

引用次数: 0

Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study. 恩杂鲁胺在生化复发性前列腺癌中的作用：来自EMBARK研究的关键发现。

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-03-27 DOI: 10.1080/14796694.2025.2479331

Neal D Shore, Henry H Woo

引用次数: 0